Pharmacogenomics (PGx) is the study of genetic influences on an individual's response to
medications. Improvements in the quality and quantity of PGx research over the past two …

Precision medicine is increasingly recognized as a promising approach to improve disease
treatment, taking into consideration the individual clinical and biological characteristics …

The pharmacological treatment of depression consists of stages of trial and error, with less
than 40% of patients achieving remission during first medication trial. However, in a large …

In this study 180 patients were consented and enrolled for pharmacogenomic testing based
on current antidepressant/antipsychotic usage. Samples from patients were genotyped by …

Despite the potential to improve patient outcomes, the application of pharmacogenomics
(PGx) is yet to be routine. A growing number of PGx implementers are leaning toward using …

Objectives Assess the potential benefits of identifying drug-gene interactions in nursing
home (NH) residents on multiple medications. Reduce the use of high-risk medications for …

Precision medicine (PM), specifically genetic-based testing, is currently used in over
140,000 individual tests to inform the clinical management of disease. Though several …

Pharmacogenomic (PGx) testing can help personalise psychiatric prescribing and improve
on the currently adopted trial-and-error prescribing approach. However, widespread …

Major depression is a frequent condition which variably responds to treatment. In view of its
high prevalence, the presence of treatment resistance in major depression significantly …

The practice of precision medicine considers a variety of sources of information to optimize
patient care. Factors such as patient demographics, clinical history, and lab test values have …